Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1998-12-04
1999-11-09
Degen, Nancy
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 245, 536 231, 536 243, 536 241, 435 6, 435375, C07H 2104, C12Q 168
Patent
active
059817321
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-13. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-13. Methods of using these compounds for modulation of G-alpha-13 expression and for treatment of diseases associated with expression of G-alpha-13 are provided.
REFERENCES:
patent: 5149797 (1992-09-01), Pederson
patent: 5770713 (1998-06-01), Imbach
patent: 5789573 (1998-08-01), Baker et al.
patent: 5856462 (1999-01-01), Agrawal
Althoefer et al., Constitutively active Galphaq and Galpha13 trigger apoptosis through different pathways,J. Biol. Chem., 1997, 272:24380-24386.
Gohla et al., The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho, J. Biol. Chem., 1998, 273:4653-4659.
Hamm, The many faces of G protein signaling, J. Biol. Chem., 1998, 273:669-672.
Jho et al., c-Jun amino-terminal kinase is regulated by Galpha12/Galpha13 and obligate for differentiation of P19 embryonal carcinoma cells by retinoic acid, J. Biol. Chem., 1997, 272:24468-24474.
Jho et al., Galpha12 and Galpha13 mediate differentiation of P19 mouse embryonal carcinoma cells in response to retinoic acid, J. Biol. Chem., 1997, 272:24461-24467.
Needham et al., Galpha12 and Galpha13 stimulate Rho-dependent tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130 Crk-associated substrate, J. Biol. Chem., 1998, 273:14626-14632.
Offermanns et al., Galpha12 and galpha13 are phosphorylated during platelet activation, J. Biol. Chem., 1996, 271:26044-26048.
Offermanns et al., Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency, Science, 1997, 275:533-536.
Plonk et al., The alpha-subunit of the heterotrimeric G protein G13 activates a phospholipase D isozyme by a pathway requiring Rho family GTPases, J. Biol. Chem., 1998, 273:4823-4826.
Voyno-Yasenetskaya et al., Galpha12 and Galpha13 regulate extracellular signal-regulated kinase and c-Jun kinase pathways by different mechanisms in COS-7 cells, J. Biol. Chem., 1996, 271:21081-21087.
Voyno-Yasenetskaya et al., Mutant alpha subunits of G12 and G13 proteins induce neoplastic transformation of Rat-1 fibroblasts, Oncogene, 1994, 9:2559-2565.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48, Feb. 1998.
Eugene Uhlmann and Anusch Peyman, Antisense Oligonucleotides: A new Therapeutic Principle, Chemical Reviews, pp. 545-546, Jun. 1990.
Trisha Gura, Antisense Has Growing Pains, Science, pp. 575-577, Oct. 1995.
Stanley Crooke, Antisense '97: A roundtable on the state of the industry, Nature Biotechnology, p. 522, Jun. 1997.
Degen Nancy
Epps Janet
Isis Pharmaceuticals , Inc.
LandOfFree
Antisense modulation of G-alpha-13 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of G-alpha-13 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of G-alpha-13 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1457803